Cizzle Biotechnology/Bould (CIZ): Strategic collaboration with SGSC
Cizzle Biotechnology (Cizzle), focused on cancer diagnostics, was spun out of the University of York to exploit the biomarker, variant CIZ1b, for early detection of different forms of lung cancer. There is high medical need for a simple blood test, to be used alongside a positive chest scan, that allows early detection of lung cancer. This should result in a significant reduction in the number of false positives, reduce the number of scans and improve patient outcomes. As part of its portfolio expansion and to increase the number of income streams, Cizzle has signed a commercial and royalty deal with respect to a clinical asset, known as AZD1656.
We are a rapidly growing, innovative corporate research & consultancy business, based in London, serving the needs of both public and private companies.
Our expert team of sector analysts and market professionals collectively have over 400 years of experience. This depth of knowledge and a reputation for integrity have built trust with investors. With effective communication and precision distribution, we help companies disseminate their investment message to interested investors, as well as advise them on strategy.
Our smaller, boutique structure allows us to provide first-class customer service and to deliver a wide range of ad-hoc services for multiple clients with different needs.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.